“Key findings: The viabilities of MCF7 and MDA‐MB‐231 cells treated by Ral (1 &mgr;M) and Res (20 &mgr;M) decreased significantly (p = 0.000) and their synergic use showed more reduction.”
“Significance: The synergic effects of Ral and Res through increased ratio of Bcl2/Bax and expressions of p53, caspase‐3 and caspase‐8 genes indicating a better therapeutic effect on breast cancer cells relative to each drug alone.”
“There was also an increase in apoptosis in the cells treated with combination use of Ral and Res in both cell lines.”